These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15553363)

  • 21. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study.
    Mahlberg R; Walther S; Eichmann U; Tracik F; Kunz D
    Arch Gerontol Geriatr; 2007; 45(1):19-26. PubMed ID: 16963137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy and safety of rivastigmine (exelon) in the confusion syndrome in the acute phase of ischemic stroke].
    Litvineneko IV; Odinak MM; Khlystov IuV; Perstnev SV; Fedorov BB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(11 Pt 2):36-41. PubMed ID: 21389938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholinesterase inhibitors and delirium after cardiac surgery.
    Yazigi A; Madi-Jebara S; Haddad F; Hayek G
    Crit Care Med; 2010 Apr; 38(4):1231. PubMed ID: 20335721
    [No Abstract]   [Full Text] [Related]  

  • 24. Rivastigmine for subcortical vascular dementia.
    Román GC
    Expert Rev Neurother; 2005 May; 5(3):309-13. PubMed ID: 15938663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rivastigmine in prevention of delirium in a 65 years old man with Parkinson's disease.
    Dautzenberg PL; Wouters CJ; Oudejans I; Samson MM
    Int J Geriatr Psychiatry; 2003 Jun; 18(6):555-6. PubMed ID: 12789683
    [No Abstract]   [Full Text] [Related]  

  • 26. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
    Gauthier S; Juby A; Morelli L; Rehel B; Schecter R;
    Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
    Small GW; Kaufer D; Mendiondo MS; Quarg P; Spiegel R
    Int J Clin Pract; 2005 Apr; 59(4):473-7. PubMed ID: 15853867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rivastigmine in the treatment of delirium in older people: a pilot study.
    Overshott R; Vernon M; Morris J; Burns A
    Int Psychogeriatr; 2010 Aug; 22(5):812-8. PubMed ID: 20353624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
    Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
    Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
    Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
    Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
    Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years.
    Farlow MR; Lilly ML;
    BMC Geriatr; 2005 Jan; 5():3. PubMed ID: 15659242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment persistency with rivastigmine and donepezil in a large state medicaid program.
    Singh G; Thomas SK; Arcona S; Lingala V; Mithal A
    J Am Geriatr Soc; 2005 Jul; 53(7):1269-70. PubMed ID: 16108961
    [No Abstract]   [Full Text] [Related]  

  • 34. [Rivastigmine against dementia in Parkinson disease?].
    Landmark K; Reikvam A
    Tidsskr Nor Laegeforen; 2007 Nov; 127(22):2973; author reply 2973-4. PubMed ID: 18026256
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting.
    Frankfort SV; Appels BA; De Boer A; Tulner LR; Van Campen JP; Koks CH; Beijnen JH
    Int J Clin Pract; 2006 Jun; 60(6):646-54. PubMed ID: 16805746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of cholinesterase inhibitors in subjects with dementia in Europe.
    Pariente A; Helmer C; Merliere Y; Moore N; Fourrier-Réglat A; Dartigues JF
    Pharmacoepidemiol Drug Saf; 2008 Jul; 17(7):655-60. PubMed ID: 18508393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Rivastigmine in a case of autopsy proved frontotemporal dementia (Pick's disease)].
    Calatayud-Noguera T; Astudillo-González A; Alvarez-Carriles JC; Temprano-Fernández T; Cortés-Velarde M; Oliva-Nacarino P
    Rev Neurol; 2009 Jun 1-15; 48(11):582-4. PubMed ID: 19472156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.